Abstracts tagged "Hydroxychloroquine"

Abstract Number: 2433 • 2016 ACR/ARHP Annual Meeting
Trends in Use of Hydroxychloroquine during Pregnancy in SLE Patients from 2001 to 2012
Bonnie L. Bermas¹, Seoyoung Kim^2,3, Krista Huybrechts⁴, Sonia Hernandez-diaz⁵, Brian T. Bateman⁶ and Rishi J. Desai⁷, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁵Harvard School of Public Health, Boston, MA, ⁶Division of Pharmacoepidemiology and Pharocoeconomics, Brigham and Women's Hospital, Boston, MA, ⁷PharmacoEpidemiology & PharmacoEconomics, Brigham & Women's Hospital, Boston, MA
Background/Purpose : Data suggest that hydroxychloroquine (HCQ) use during systemic lupus erythematosus (SLE) pregnancies improves outcomes. In the past decade, single-center studies report that a…
Abstract Number: 2453 • 2016 ACR/ARHP Annual Meeting
The Prevention, Screening, and Treatment of Congenital Heart Block from Neonatal Lupus: A Survey of Provider Practices
Megan E. B. Clowse¹, Amanda M. Eudy², Bonnie L. Bermas³, Eliza Chakravarty⁴, Lisa R. Sammaritano⁵ and Christina D. Chambers⁶, ¹Rheumatology, Duke University School of Medicine, Durham, NC, ²Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Edmond, OK, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Pediatrics, University of California, San Diego, La Jolla, CA
Background/Purpose: There are presently no official guidelines about the prevention, screening, and treatment of congenital heart block (CHB) due to maternal Ro antibodies. The objective…
Abstract Number: 2456 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results from a Multicenter Italian Cohort over 20 Years of Experience
Maria Grazia Lazzaroni¹, Laura Andreoli¹, Cecilia B. Chighizola², Teresa Del Ross³, Maria Gerosa⁴, Anna Kuzenko³, Maria Gabriella Raimondo⁴, Andrea Lojacono⁵, Sonia Zatti⁵, Francesca Ramazzotto⁵, Laura Trespidi⁶, Pier Luigi Meroni⁷, Vittorio Pengo³, Amelia Ruffatti³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ³Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁴University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶L.Mangiagalli Obstetric Clinic, IRCSS Cà Granda, Ospedale Maggiore of Milano, Milano, Italy, ⁷Hospital G.Pini, University of Milano, IRCSS Instute Auxologico Italiano, Milano, Italy
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results From a Multicenter Italian Cohort Over 20 Years Of Experience Background/Purpose: Antiphospholipid antibodies (aPL)…
Abstract Number: 340 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine: A Potential Treatment for Osteoporosis By Osteoclast Inhibition!
Tim Both¹, Paul L. van Daele² and Bram Van der Eerden¹, ¹Internal Medicine, Erasmus MC, Rotterdam, Netherlands, ²Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: We recently showed that patients with primary Sjögren Syndrome (pSS) have significantly higher bone mineral density (BMD) in the lumbar spine and femoral neck…
Abstract Number: 3134 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Is Not Effective in Reducing Symptoms of Hand Osteoarthritis: Results from a Placebo-Controlled Randomised Trial
Sarah R. Kingsbury¹, Puvan Tharmanathan², Ada Keding³, Sarah Ronaldson³, Andrew Grainger⁴, Richard J. Wakefield⁵, Catherine Arundel³, Fraser Birrell⁶, Michael Doherty⁷, Tonia Vincent⁸, Fiona E Watt⁹, Krysia Dziedzic¹⁰, Terence W. O'Neill¹¹, Nigel K Arden¹², David L Scott¹³, John Dickson¹⁴, Toby Garrood¹⁵, Michael Green^16,17, Ajit Menon¹⁸, Tom Sheeran¹⁹, David Torgerson³ and Philip G. Conaghan⁴, ¹Section of Musculoskeletal Disease, Chapel Allerton Hospital, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Leeds, United Kingdom, ²University of York, York, United Kingdom, ³Health Sciences, University of York, York, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁷Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, ⁸University of Oxford, London, Great Britain, ⁹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ¹⁰Institute for Primary Care and Health Sciences, Keele University, Staffordshire, United Kingdom, ¹¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ¹²Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ¹³Department of Rheumatology, King's College London, London, United Kingdom, ¹⁴South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom, ¹⁵Rheumatology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, ¹⁶York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ¹⁷Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom, ¹⁸Haywood Hospital, Stoke-On-Trent, United Kingdom, ¹⁹Cannock Chase Hospital, Cannock, United Kingdom
Background/Purpose: Synovitis is prevalent in OA and associated with pain. Hydroxychloroquine (HCQ) is used routinely for treating synovitis in inflammatory arthritis. The primary aim of…
Abstract Number: 435 • 2016 ACR/ARHP Annual Meeting
It Takes Two, an Interdisciplinary Approach to Increasing Hydroxychloroquine Screening Adherence
Christina Downey¹, Tombra Govina¹ and Eric Newman², ¹Geisinger Medical Center, Danville, PA, ²Department of Rheumatology, Geisinger Medical Center, Danville, PA
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used rheumatologic drug that carries a risk for irreversible retinal toxicity. The incidence of adverse effect increases to greater…
Abstract Number: 436 • 2016 ACR/ARHP Annual Meeting
Are Providers Recommending Appropriate Screening for Hydroxychloroquine-Induced Retinal Toxicity to Their Patients?
Sarah Haserodt¹, Chris Tonner², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Although well tolerated by most patients, hydroxychloroquine (HCQ) can cause irreversible retinal damage. The American Association of Ophthalmology (AAO) 2016 Guidelines recommend a baseline…
Abstract Number: 652 • 2016 ACR/ARHP Annual Meeting
The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy
Daniel Erhardt¹, Brian C Sauer², Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴ and Grant W. Cannon², ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We recently reported that real-world persistence in Veteran’s Affairs (VA) patients was lower in Rheumatoid arthritis (RA) patients receiving triple therapy [methotrexate (MTX), sulfasalazine…
Abstract Number: 425 • 2015 ACR/ARHP Annual Meeting
Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus
Julie Barsalou¹, Nathalie Costedoat-Chalumeau², Cesar Fors-Nieves³, Ummara Shah⁴, Patrick Brown⁵, Carl Laskin⁶, Nathalie Morel², Kateri Levesque⁷, Jill P. Buyon⁸, Earl Silverman⁹ and Peter M. Izmirly¹⁰, ¹Pediatric Rheumatology, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, ²Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ³Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, ⁵University of Toronto, Toronto, ON, Canada, ⁶Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁷Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, ⁸NYU School of Medicine, New York, NY, ⁹Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Biopsy specimens of cutaneous neonatal lupus (cNL) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in connective…
Abstract Number: 484 • 2015 ACR/ARHP Annual Meeting
Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use
Myriam Guevara¹, Bernard NG¹ and Nancy Gove², ¹Rheumatology, University of Washington, Seattle, WA, ²Biostatistics, Seattle Children's, Seattle, WA
Background/Purpose: Despite remarkable improvements in RA treatment, there is evidence indicating that the mortality gap between RA patients and the general population is not closing.…
Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting
Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.
Grant W. Cannon¹, Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴, Derek Tang⁵, Bradley S. Stolshek⁵ and Brian Sauer⁶, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA). Randomized controlled trials…
Abstract Number: 2483 • 2015 ACR/ARHP Annual Meeting
Adherence to 2011 American Academy of Ophthalmology Guidelines to Perform Objective Screening Tests for Detection of Antimalarial Retinal Toxicity Is Suboptimal
Sarah Haserodt¹, Chris Tonner², Sara G. Murray³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/ Rheumatology, UCSF/ San Francisco VA, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, CA
Background/Purpose: American Academy of Ophthalmology (AAO) 2011 guidelines recommend that patients receiving hydroxychloroquine (HCQ) or chloroquine (CQ) undergo regular screening for retinal toxicity with 1…
Abstract Number: 2374 • 2014 ACR/ARHP Annual Meeting
Use of Hydroxychloroquine Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients
Jose Felix Restrepo¹, Inmaculada del Rincon², Emily Molina³, Daniel Battafarano⁴ and Agustin Escalante⁵, ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine/Clinical Immunology, UTHSCSA, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center, San Antonio, TX, ⁴Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, ⁵Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality in rheumatoid arthritis (RA). CVD risk factor reduction, such as reducing…
Abstract Number: 1846 • 2014 ACR/ARHP Annual Meeting
The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients
Michael Shapiro¹ and Yair Levy², ¹Haim Lebanon 55, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Internal Medicine E, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Accelerated atherosclerosis and cardiovascular disease are the main causes of mortality in Rheumatoid Arthritis (RA). The anti-malarial drug Hydroxychloroquine (HCQ) has long been used…
Abstract Number: 1614 • 2013 ACR/ARHP Annual Meeting
Hydroxychloroquine Reverse The Elevation Of Interferon-Alfa Initiated By TLR-9 Agonist Which Irresponsive To Glucocorticoid
Ou Jin¹, Xi Zhang¹, Lingkai Fang¹, Qiuxia Li¹, Hongyue Huang¹, Zhiming Lin², Zetao Liao¹, Dongfang Lin¹, Chengcheng Hou¹ and Jieruo Gu³, ¹Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ²Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by chronic stimulation of the innate immune system by endogenous nucleic acids through toll-like receptors (TLRs) pathway, which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].